AbbVie News Center

SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026

AbbVie's leadership in Inflammatory Bowel Disease (IBD) research programs Latest long-term and real-world data with ...
AbbVie News Center

AbbVie Presents New Phase 3 AFFIRM Data Showing Clinical and Endoscopic Outcomes With Subcutaneous SKYRIZI® (risankizumab-rzaa) in Patients With Moderately to Severely Active ...

Higher rates of endoscopic remission and ulcer-free endoscopy were observed following subcutaneous SKYRIZI® (risankizumab-rzaa)treatment versus placeboi Results build on previously reported ...
AbbVie News Center

New SKYRIZI® (risankizumab-rzaa) and RINVOQ® (upadacitinib) Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel Disease

New Phase 3 AFFIRM data show higher rates of clinical and endoscopic response in Crohn's disease patients treated with subcutaneous SKYRIZI versus placebo across all efficacy endpoints ...